Eli Lilly LLY Verzenio — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's verzenio — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's verzenio — revenue?
- Eli Lilly (LLY) reported verzenio — revenue of $1.3B in Q1 2026.
- How has Eli Lilly's verzenio — revenue changed year-over-year?
- Eli Lilly's verzenio — revenue increased by 12.3% year-over-year, from $1.16B to $1.3B.
- What is the long-term trend for Eli Lilly's verzenio — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's verzenio — revenue has grown at a 43.5% compound annual growth rate (CAGR), from $1.35B to $5.72B.
- What does verzenio — revenue mean?
- This metric represents the total gross sales generated from the global commercialization of a specific oncology therapeutic product line. It reflects the market adoption, pricing power, and clinical demand for this targeted therapy within the broader cancer treatment portfolio. Tracking this revenue stream provides insight into the company's competitive positioning in the oncology market and the success of its specialized pharmaceutical product lifecycle management.